FIELD: cell biology.
SUBSTANCE: present invention relates to the field of cell biology and medicine, in particular to a method for obtaining a biomedical cellular product for the treatment of oncological, neurodegenerative, autoimmune and endocrine diseases and a product obtained by this method. To implement the method, first, an autologous mononuclear leukoconcentrate (MNC LC) is obtained from the bone marrow or from peripheral blood. After that, a line of autologous hematopoietic stem cells (HSC) or hematopoietic progenitor cells (HPC) with CD34+, CD45+, HLA DR+ markers is obtained. Next, a line of disease-intact autologous regional mesenchymal stem cells (MSCs) or somatic cells is obtained and their cell mass is increased. At the next stage, reprogramming of said MSCs or somatic cells into XEN-like pluripotent cells is carried out. Then, cell-engineering homotopic replacement of HSC and/or HPC nuclei with nuclei of XEN-like cells or whole XEN-like cells is carried out. At the last stage, the reduced HSC and/or HSC are combined with MNC LC.
EFFECT: invention makes it possible to restore the sanogenetic regulatory and regenerative potential of damaged own HSCs and provide them with the necessary and sufficient amount in the body.
7 cl, 4 dwg, 4 tbl
